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Available online 22 July 2017Radiographs of hands and feet are traditionally the images that are used to assess structural damage progression
in drug trials in patients with rheumatoid arthritis, aiming at proving the disease modifying capacity of a drug.
Although treatment has largely improvedover the past decade and consequently radiographic progression is lim-
ited in control arms in clinical trials, recent trials are still able to show inhibition of structural progression by new
drugs. The requirements for the successful use of radiographic progression as an outcome in rheumatoid arthritis
trials will be discussed in this paper.ogy, C1R
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Clinical trialsDrug treatment in RA traditionally distinguishes treatment with
symptom modifying and disease modifying antirheumatic drugs
(SMARDs and DMARDs). Diseasemodification is based on the preserva-
tion or normalisation of physical function as well as inhibition of struc-
tural damage progression. Traditionally, structural damage is assessed
on radiographs of hands and feet, measuring both bone resorption as
erosions and cartilage degradation as joint space narrowing. Radio-
graphs of hands and feet provide a good representation of the overall
damage that may also occur in large joints [1]. Over the years, it has
been proven useful to make the distinction between SMARD and
DMARDs particularly by assessing damage on radiographs. It has also
become clear that progression of damage can be inhibited by many dif-
ferent DMARDs and that in general the biological (b) and targeted syn-
thetic (ts) DMARDs are more efficacious than the conventional
synthetic (cs) DMARDs. It has been proven also that inflammation in in-
dividual joints results in damage of that particular joint [2]. Moreover,
overall disease activity is directly related to functional disability and is
leading to structural joint damage [3,4]. In addition, structural damage
contributes to functional disability [5]. As structural damage is largely ir-
reversible, physical disability caused by structural damage is irrevers-
ible, while the function loss related to disease activity may still be
reversible [6]. Drug treatment of RA therefore focuses on reducing in-
flammation and preventing joint damage, thereby improving function
and reducing disability. Structural damage is also related to reduced
work participation. In a recent analysis, an increase of 10 points in the-41, Leiden University
andewe@rlandewe.nl
n open access article underbaseline damage score was associated with a 9.6% decrease in the
odds of achieving a favourable employment status [7].
Initially, the usual duration of trials assessing structural damage was
52 weeks. Later, it became clear that 24 weeks is a sufficient follow-up
period and even trials with a follow-up as short as 12 weeks could
show progression of structural damage [8]. The progression observed
in the control group largely determines the possibility of showing an in-
hibitory effect by an effective drug. However, it is evident that the level
of progression observed in clinical trials has decreased over the years,
both in the actively treated and the control groups [9]. Moreover, in
the first executed trial in the late nineties the observed yearly progres-
sion rate in the control group was similar to the estimated yearly pro-
gression rate at baseline. In more recent trials, the observed
progression was much lower than the expected progression based on
the rate of progression at baseline. One of the explanations is a better
overall standard of care. Furthermore, ethical considerations and the
availability of effective treatments prohibit duration of placebo treat-
ment sufficiently long to pick up changes. Typically, the placebo period
is limited to 12–16 weeks. Moreover, there is a mandatory early escape
to switch to an effective treatment in case of clinical inefficacy, and this
has an immediate impact on the progression of structural damage.
Data of structural progression are usually presented on a group level
as the mean progression, and on a patient level. The mean progression
score is a difficult to interpretfigure because it is usually based on highly
skewed data: while many patients do not show any change, a minority
either shows an improvement or a deterioration. The patient-level in-
formation is frequently presented as the percentage of patients showing
progression above a certain cut-off, but ideally all individual patient
data should be presented in a cumulative probability plot, showing
the coherence and the number of patients with improvement and dete-
rioration [10]. While the mean progression in the control arms of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mean progression scores of only 1 unit [9]. This makes people argue if
a mean reduction of e.g. 0.5 units is still clinically relevant. The mean
progression score is indeed the best primary endpoint to assess the effi-
cacy of a drug in comparison to placebo or another drug, but it should
not be used to assess the clinical relevance. The same trial result may
also be presented as ‘the likelihood of radiographic progression above
5 units per year decreases from 15% to 5% with treatment A instead of
treatment B’. This gives already a better impression on the clinical rele-
vance. However, the real clinical relevance of structural damage can
only be based on cohort studies.
Because of the trend of lower progression rates over the years, we
have proposed the structural integrity margin [11]. This concept as-
sumes that a new treatment should show zero progression, while
allowing some variation around zero due to measurement error. This
so called structural integrity margin should be based on progression
scores found in historic trials with licensed bDMARDs that have obtain-
ed a structural claim. This would imply awithin group comparison as an
alternative to superiority against placebo. If the mean progression score
including the 95% confidence interval is entirely below the structural in-
tegrity margin, maintenance of structural integrity can be declared.
Given the limited progression observed in many trials, the question
raises if it is still useful to use radiographs as anoutcome in clinical trials.
There are several arguments pro using radiographs. First, while the
overall trend of radiographic progression is a decreasing one, still in re-
cent trials observed radiographic progression was sufficient to discrim-
inate between groups and formally prove inhibition of radiographic
progression. This was both in trials using MTX plus placebo in MTX-
inadequate responders or MTX in MTX-naïve patients as a control
group [12]. The prevailing requirement for showing inhibition of pro-
gression is sufficient progression in the control arm. Appropriate trials
include patients with a high risk of radiographic progression, based on
(for instance) presence of aCCP or rheumatoid factor, baseline damage
and elevated CRP. While trials formally prove overall inhibition, most
inhibition is usually observed in the subgroups with relatively high
baseline radiographic damage present. The usefulness of these predic-
tors for radiographic progression has been recently shown in post-hoc
analyses of the ORAL-SCAN trial with tofacitinib [13]. Moreover, there
are populations such as the Japanese, which constitutively show a
high level of progression [14]. Consequently, the selection of the correct
study population is essential. Second, the EMA has proposed radio-
graphs as a ‘safety measure’ in their draft guidance document for RA
[15]. They differentiate between using radiographs as an outcome - to
show inhibition of progression and to have this in the label - and
using radiographs to document that there is no important deterioration.
For the latter, they propose structural damage of hands and feet to be
measured routinely by radiographs in the pivotal long-term trials, as a
safety check to reassure that structural damage does not deteriorate
during treatment, e.g. compared to an active comparator. A formal
non-inferiority test is not required.
Are there alternative imaging measures? Not really at this point in
time. The EMA accepts MRI as an additional, supportive imaging meth-
od, but not as a replacement for radiographs [15]. MRI has shown pre-
dictive validity in predicting progression of structural progression on
radiographs over 24 weeks by MRI over 12 weeks, as well as 52-week
progression on radiographs by 24-week progression on MRI [16]. How-
ever, MRI in RA is more difficult to standardise, and time-consuming,
which makes it less feasible. As a consequence, MRI can only be per-
formed according to appropriate regulatory standards in centres of ex-
cellence in the field of MRI, which consequently impedes feasibility of
trial conduct and generalisability of results. Along similar lines, ultraso-
nography, while very popular in rheumatology, will not easily become a
surrogate for assessing structural progression. The technique is highly
operator-dependent, time consuming and unfeasible in trials, and a uni-
fied and broadly accepted scoring system is lacking. All other imaging
techniques that potentially can be used to monitor structuralprogression in RA are -from a regular point of view- highly experimen-
tal, and several aspects of validity are currently lacking.
A method to increase the sensitivity of structural damage assessed
on radiographs could be to change the reading process. Typically, two
readers score all radiographs independently, blinded to patient identity,
treatment group and time order. The average score of the two readers is
used as the primary endpoint. Two changes could be implemented to
increase sensitivity as well as increase precision: unblind the time
order (increases sensitivity) and use (the average score of) three
readers (increasing precision) [17,18].
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